Stromal thrombospondin-1 expression is a prognostic indicator and a new marker of invasiveness in intraductal papillary-mucinous neoplasm of the pancreas.

The invasion of intraductal papillary-mucinous neoplasm (IPMN) is sometimes difficult to diagnose using only ordinary hematoxylin-eosin sections. The aim of this study was to evaluate the invasion of IPMN more precisely using thrombospondin-1 (TSP1) immunohistochemistry as a useful adjunct to morphological examination. Eighty patients that underwent primary resection for pancreatic IPMNs were retrospectively analyzed. The 80 IPMNs were studied for the expression of TSP1, MUC1-CORE, MUC2, and MUC5AC. The cases were evaluated for dysplasia, the presence of invasion, hisological subtypes, and survival. The 80 IPMNs were classified into 29 intraductal papillary-mucinous adenomas (IPMAs), 10 borderline IPMNs, 18 noninvasive intraductal papillary-mucinous carcinomas (IPMCs), and 23 invasive IPMCs according to the WHO classification. Invasive IPMCs were further divided into 12 minimally invasive IPMCs (MI-IPMCs) and 11 invasive carcinomas originating from IPMCs (IC-IPMCs) according to the Japan Pancreatic Society classification. The rate of strongly positive cases with more than 30% of the cancer stroma area expressing TSP1 was significantly higher in MI-IPMC and IC-IPMC than in noninvasive IPMC (P = 0.035, 0.005). Furthermore, patients in the strongly positive group had a significantly poorer prognosis compared to patients in the negative-weakly positive group (P = 0.008, log-rank test). Of the 80 tumors, 22 were classified into gastric-, 45 into intestinal-, 7 into pancreatobiliary-, and 6 into oncocytic-type IPMNs according to criteria described previously. The cases with a strongly positive expression of TSP1 were frequently detected in the pancreatobiliary and oncocytic types (P = 0.001). In conclusion, stromal TSP1 expression is a prognostic indicator and a new marker of invasiveness in IPMN.

[1]  T. Itoi,et al.  Pancreatic Juice Cytology and Subclassification of Intraductal Papillary Mucinous Neoplasms of the Pancreas , 2007, Pancreas.

[2]  M. Fukayama,et al.  Periostin deposition in the stroma of invasive and intraductal neoplasms of the pancreas , 2008, Modern Pathology.

[3]  S. Hirohashi,et al.  Expression of Laminin-5-γ-2 Chain in Intraductal Papillary-Mucinous and Invasive Ductal Tumors of the Pancreas , 2001, Modern Pathology.

[4]  Koichi Suda,et al.  Cystic Neoplasm of the Pancreas: A Japanese Multiinstitutional Study of Intraductal Papillary Mucinous Tumor and Mucinous Cystic Tumor , 2004, Pancreas.

[5]  Kazuhiro Yoshida,et al.  Comparison of histologic subtype and growth pattern in intraductal papillary-mucinous carcinoma of the pancreas. , 2008, Oncology reports.

[6]  N. Adsay,et al.  Cystic lesions of the pancreas , 2007, Modern Pathology.

[7]  S. Tripp,et al.  Histologic, Immunohistochemical, and Molecular Classification of 52 IPMNs of the Pancreas , 2009, Applied immunohistochemistry & molecular morphology : AIMM.

[8]  Olca Basturk,et al.  Pathologically and Biologically Distinct Types of Epithelium in Intraductal Papillary Mucinous Neoplasms: Delineation of an “Intestinal” Pathway of Carcinogenesis in the Pancreas , 2004, The American journal of surgical pathology.

[9]  Y. Kanai,et al.  Minimally Invasive Intraductal Papillary-mucinous Carcinoma of the Pancreas: Clinicopathologic Study of 104 Intraductal Papillary-mucinous Neoplasms , 2008, The American journal of surgical pathology.

[10]  T. Urashima,et al.  Long-term Surgical Outcome of Noninvasive and Minimally Invasive Intraductal Papillary Mucinous Adenocarcinoma of the Pancreas , 2002, World Journal of Surgery.

[11]  P. Bornstein,et al.  Thrombospondins: structure and regulation of expression , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  Masafumi Nakamura,et al.  Pancreatic Juice Cytology in IPMN of the Pancreas , 2005, Pancreatology.

[13]  M. Ishida,et al.  Characteristic Clinicopathological Features of the Types of Intraductal Papillary-Mucinous Neoplasms of the Pancreas , 2007, Pancreas.

[14]  R. Hruban,et al.  Molecular classification of neoplasms of the pancreas. , 2009, Human pathology.

[15]  I. Sargiannidou,et al.  The Role of Thrombospondin-1 in Tumor Progression , 2001, Experimental biology and medicine.

[16]  K. Takaori.  Current understanding of precursors to pancreatic cancer. , 2007, Journal of hepato-biliary-pancreatic surgery.

[17]  R. Cote,et al.  Immunohistochemical detection of thrombospondin-1 in formalin-fixed, paraffin-embedded tissue. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[18]  P. Majerus,et al.  A thrombin-sensitive protein of human platelet membranes. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Chari,et al.  International Consensus Guidelines for Management of Intraductal Papillary Mucinous Neoplasms and Mucinous Cystic Neoplasms of the Pancreas , 2006, Pancreatology.

[20]  H. Kijima,et al.  Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma. , 2002, International journal of oncology.

[21]  D. Roberts,et al.  Regulation of tumor growth and metastasis by thrombospondin‐1 , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  R. Hruban,et al.  Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study , 2005, Virchows Archiv.

[23]  K. Dameron,et al.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. , 1994, Science.

[24]  S. Yonezawa,et al.  The expression of several types of mucin is related to the biological behavior of pancreatic neoplasms. , 2002, Journal of hepato-biliary-pancreatic surgery.